Today (Wednesday, August 18, 2021), Renascience announces that it has received approval from the Tokyo Stock Exchange, Inc. for the initial listing of its shares on the Tokyo Stock Exchange Mothers.
The listing date is scheduled for September 24, 2021 (Friday).
We would like to take this opportunity to express our sincere gratitude to our business partners, shareholders, and all other stakeholders for the support and patronage to date.
With the listing of our shares, we will continue our efforts to solve medical issues that are also socially important, under our corporate philosophy “We devote ourselves to research and development of various modalities (pharmaceuticals, medical devices, artificial intelligence (AI), etc.) in the medical setting to solve problems in the medical field, and create new medical care to enable people to enjoy lifelong health, both physically and mentally.” We will greatly appreciate your continuous guidance and encouragement.
Note: This press release is prepared solely for the purpose of announcing the approval of the initial listing of the Renascience’s shares on the Tokyo Stock Exchange, and does not constitute an offer to sell or the solicitation of an offer to buy any securities within or outside Japan. Investors should review “the prospectus for the issuance of new shares and the secondary offering of shares” (and any amendments thereto) issued by Renascience prior to making any investment decisions. “The prospectus for the issuance of new shares and the secondary offering of shares” (and any amendments thereto) may be obtained from the underwriters.